


**Product Name** : Enerisant  
**Cat. No.** : PC-72276  
**CAS No.** : 1152747-82-4  
**Molecular Formula** : C<sub>22</sub>H<sub>30</sub>N<sub>4</sub>O<sub>3</sub>  
**Molecular Weight** : 398.507  
**Target** : Histamine Receptor  
**Solubility** : 10 mM in DMSO



## Biological Activity

Enerisant (S091,TS-091) is a potent, selective **histamine H3 receptor** antagonist/inverse agonist with IC<sub>50</sub> of 2.89 and 14.5 nM against hH3R and rH3R, respectively.

Enerisant inhibited R- $\alpha$ -methylhistamine-stimulated [35S]GTP $\gamma$ S binding to human histamine H3 receptor and rat histamine H3 receptor with IC<sub>50</sub> values of 1.06 and 10.05 nM, respectively, inhibited basal [35S]GTP $\gamma$ S binding to human histamine H3 receptor with an EC<sub>50</sub> value of 0.357 nM.

Enerisant displays negligible effects on binding to human histamine H1, H2, and H4 receptor subtypes, as well as negligible affinities for 66 other receptors, transporters, and ion channels at 1-10  $\mu$ M.

Oral administration of enerisant hydrochloride attenuated the dipsogenia response on R- $\alpha$ -methylhistamine-induced dipsogenia in rats, the intraperitoneal administration of enerisant hydrochloride increased the total extracellular acetylcholine levels in the mPFC.

Enerisant hydrochloride significantly decreased slow-wave deep sleep at doses of 1-10 mg/kg (P < 0.01-0.05). Enerisant hydrochloride (1, 3 and 10 mg/kg, p.o.) did not affect the accumulated locomotor activity time at up to 7 hours after administration.

## References

Noriko Hino, et al. *J Pharmacol Exp Ther.* 2020 Nov;375(2):276-285.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com